Philippe Boucheron
Deputy Chief Life Sciences Investment @ Bpifrance
Paris, France
Philippe Boucheron is a private equity investor at Bpifrance in Paris focused on Medical and Health Care. Mr. Boucheron is Investment Director at Bioam, a biotechnology investment fund. From 1993 to 1996, Mr. Boucheron worked at BioCapital LP, one of Canada’s largest venture capital funds focusing on biotech. From 1997 to 2000, he directed the mid-caps equity research team at the Paris office of ING Barings Ferri, where he spent a significantamount of his time following French and European BioTech companies. Mr. Boucheron holds a degree in Biochemical Engineering and Microbial Genetics from the Institut National des Sciences Appliqués in Toulouse He also has an MSc in Biochemical Engineering from the Ecole Polytechique of Montreal and a MBA from INSEAD.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Philippe Boucheron invests in
Stages Philippe Boucheron invests in
Countries Philippe Boucheron invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (29%)
- Health Care 2 (29%)
- Therapeutics 2 (29%)
- Biotechnology 2 (29%)
- Genetics 1 (14%)
Stage
- Private Equity 2 (29%)
- Series A 1 (14%)
- Series B 1 (14%)
- Funding Round 1 (14%)
- Post-IPO Equity 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
HEPTA Medical
|
HEPTA Medical develops a sensor, embedded into a bronchoscopic or percutaneous ablation catheter, which provides temperature-based feedback. This enables real-time dosing to precisely target and ablates pulmonary nodules, the precursor of lung cancer, without the need for surgery or radiation. | $6.3M / Series A / Sep 04, 2024 | |
Advicenne
|
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $17.6M / Mar 20, 2017 | |
Advicenne Pharma SA
|
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. | $17.6M / Private Equity / Mar 20, 2017 | |
|
Advicenne
|
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $18.2M / Private Equity / Mar 20, 2017 | |
|
Advicenne
|
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $18.2M / Private Equity / Mar 20, 2017 | |
IntegraGen
|
IntegraGen is a French biotech company based on the Genopole life science park in Evry, near Paris. It leverages its unique intellectual property, research expertise and privileged access to sample libraries to develop molecular markers for central nervous system and metabolic diseases. IntegraGen notably uses its proprietary technology platformsto provide genomics services to the pharmaceutical industry, biotech firms and other research providers. | $8.8M / Series B / Nov 17, 2005 | |
|
Advicenne
|
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $3M / Post-IPO Equity |
Co-Investors
About Bpifrance
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Bpifrance Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adrien Neel
Investment Director
|
|||
Arnaud Legardeur
Investment Director
|
|||
Cédric Clement
Senior Investment Director | Bpifrance Deeptech Venture
|
|||
Charlotte Corbaz
Investment Drector - Large Venture
|
|||
Clarisse Blandin
Investment director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Philippe Boucheron invest in?
Philippe Boucheron invests primarily in Medical, Health Care and Therapeutics startups, most often at Private Equity and Series A stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Philippe Boucheron?
Public channels for Philippe Boucheron include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Philippe Boucheron last invest?
The most recent investment recorded for Philippe Boucheron closed in Sep 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
